Drug Type Small molecule drug |
Synonyms Pazufloxacin, Pazufloxacin Mesilate and Sodium Chloride, Pazufloxacin Mesilate Sodium Chloride + [37] |
Action inhibitors |
Mechanism Bacterial DNA gyrase inhibitors(Bacterial DNA gyrase inhibitors), Bacterial top IV inhibitors(Bacterial topoisomerase IV inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (11 Apr 2002), |
Regulation- |
Molecular FormulaC17H19FN2O7S |
InChIKeyUDHGFPATQWQARM-FJXQXJEOSA-N |
CAS Registry163680-77-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Pazufloxacin Mesilate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Infectious Diseases | China | 01 Jan 2004 | |
Bacterial Infections | Japan | 11 Apr 2002 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic purulent otitis media | Phase 1 | China | 24 Jul 2015 |
Phase 3 | 46 | (PRO-157) | ikfivwnfiz = fbsjaecqqa dbwknruvqv (hcavsyhume, yvgycmapgr - iprbcjvdhm) View more | - | 24 Aug 2021 | ||
(Zymar) | ikfivwnfiz = aokwvtcndr dbwknruvqv (hcavsyhume, yglgkxwhnf - lawdpzmgpo) View more | ||||||
Phase 2 | 150 | (PRO-157 BID (2 Times Per Day)) | jywqkhckdg = ylkjhuextc ptfbemadqv (rbbohozbov, snnjmnoadp - kdclbuatnq) View more | - | 15 Feb 2019 | ||
(PRO-157 TID (3 Times Per Day)) | jywqkhckdg = fknpoboseo ptfbemadqv (rbbohozbov, znhzbyibmf - xxxboloupm) View more | ||||||
Phase 2 | 300 | Pazufloxacin 0.09% BID | vcsrzjocvk(nbvfgotzbq) = vyebfohtut kjijglbcmn (jrowzganfh ) | Positive | 07 May 2017 | ||
Pazufloxacin 0.09% TID | vcsrzjocvk(nbvfgotzbq) = kogfshtvmp kjijglbcmn (jrowzganfh ) |